Document is current
Any future updates will be listed below
-
Authors
Shanmugam, Vignesh
Tokcan, Neriman
Chafamo, Daniel https://orcid.org/0009-0001-8877-5913
Sullivan, Sean https://orcid.org/0009-0001-0435-2957
Borji, Mehdi
Martin, Haley
Newton, Gail
Nadaf, Naeem https://orcid.org/0000-0002-7805-8523
Hanbury, Saoirse
Barrera, Irving
Cable, Dylan
Weir, Jackson https://orcid.org/0000-0001-8741-1344
Ashenberg, Orr
Pinkus, Geraldine
Rodig, Scott https://orcid.org/0000-0003-1761-9769
Uhler, Caroline
Macosko, Evan https://orcid.org/0000-0002-2794-5165
Shipp, Margaret https://orcid.org/0000-0002-3949-6897
Louissaint, Abner Jr.
Chen, Fei https://orcid.org/0000-0003-2308-3649
Golub, Todd R. https://orcid.org/0000-0003-0113-2403
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA242457)
- License Information
-
More Information
Article History
Received: 28 March 2025
Accepted: 3 December 2025
First Online: 20 December 2025
Competing interests
: S.J.R. receives research support from Bristol Myers Squibb, Coherus, and KITE/Gilead. He is a member of the Scientific Advisory Board of Immunitas Therapeutics. F.C. is an academic founder of Curio Biosciences and Doppler Biosciences and a scientific advisor for Amber Bio. F.C.‘s interests were reviewed and managed by the Broad Institute per its conflict-of-interest policies. E.Z.M. is a founder of Curio Bioscience, Inc. M.A.S. has received research funding from Bristol Myers Squibb, AstraZeneca, Bayer, AbbVie, Genentech, and Novartis, and has served on advisory boards for Bristol Myers Squibb and AstraZeneca. T.R.G. is a paid advisor and/or equity holder in Dewpoint Therapeutics, Sherlock Biosciences, Amplifyer Bio, and Braidwell, Inc. The remaining authors declare no competing interests.
